<DOC>
	<DOCNO>NCT01795677</DOCNO>
	<brief_summary>JAK2 inhibitor RUXOLITINIB allogeneic hematopoietic stem cell transplantation ( HSCT ) patient primary secondary myelofibrosis : prospective phase II</brief_summary>
	<brief_title>JAK2 Inhibitors RUXOLITINIB Patients With Myelofibrosis</brief_title>
	<detailed_description>JAK2 inhibitor RUXOLITINIB allogeneic hematopoietic stem cell transplantation ( HSCT ) patient primary secondary myelofibrosis</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Age 18 69 year No comorbidity contraindicate transplantation : Severe respiratory failure define dyspnea grade III Severe cardiac failure define EF &lt; = 30 % Severe renal failure define creatinine clearance &lt; 30 ml/min dialysis Dementia nonability give inform consent protocol Major alteration performance status define ECOG &gt; 2 Severe liver disease define cirrhosis bilirubin &gt; 2 x ULN , AST/ALT &gt; 5 x ULN Primary secondary myelofibrosis diagnose accord WHO definition ( Tefferi , et al 2007 ) Palpable splenomegaly splenomegaly measure imagery ( maximum size &gt; 15 cm ultrasound scan , Magnetic Resonance Imaging computer tomography ) Disease intermediate high risk accord publish criterion summarize follow : At least one criterion among follow : Haemoglobin &lt; 100 gr/L ( unrelated medication toxicity ) Leucocytes &lt; 4 G/L ( unrelated medication toxicity ) &gt; 25 G/L Poor prognosis cytogenetics : complex karyotype , abnormality chromosomes 5 , 7 17 , +8 , 12p , inv ( 3 ) , 11q23 Two criterion among follow criterion : General symptom ( weight lose &gt; 10 % less 6 month , night swears , specific fever &gt; 37.5Â°C ) Peripheral blastosis &gt; 1 % observe least twice Thrombocytopenia &lt; 100 G/L ( unrelated treatment toxicity ) Myelofibrosis transform acute leukaemia 20 % blast blood bone marrow Previous treatment JAK2 inhibitor Thrombopenia &lt; 50 G/L Comorbidities contraindicate transplantation Comorbidity score Sorror &gt; 3 Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>JAK2 inhibitor RUXOLITINIB</keyword>
	<keyword>Primary secondary myelofibrosis</keyword>
</DOC>